Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 9

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 9
---
 Net Sales $ in millions China Rest of World FY24 Net Sales by Geography(1) 51% China | 13% Japan | 7% Korea | 6% U.S. | 22% Rest of World May not sum to 100% due to rounding. Reflects management projections in the definitive proxy. Reflects a burn down of distributor inventory. (2) EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Represents a significant premium across multiple measures and a price meaningfully higher than the market’s expectations prior to the Alcon merger announcement, particularly given STAAR’s lower go-forward growth profile. On February 11, 2025, after STAAR announced its 4Q 2024 results, STAAR’s stock price declined to $15.09 and traded in the range of $15.09 to $20.27 through the date of the Alcon merger announcement on August 5, 2025. Executive Summary Based on 90-day VWAP for period ending August 4, 2025, which was the day before announcement. Based on August 4, 2025, closing price, which was the day before announcement. Based on available brokers with current price targets as of August 1, 2025. Median premium paid of 26% across comparable transactions. Comparable transactions based on U.S. cash-only MedTech deals announced since 2015 with deal value above $500mm. $28.00 per share all-cash consideration provides STAAR stockholders compelling, certain, and immediate cash value at a significant premium. premium to median sellside analyst price target of $19(3) median premium paid in comparable transactions(4) premium to 90-Day VWAP of $18(1) premium to unaffected share price(2) 59% 51% 47% ~2.0x I EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR faces sustained challenges as a standalone company and management projections do not signal a return to historical growth rates or profitability. Although management has made progress mitigating some near-term challenges, STAAR faces ongoing business headwinds that will continue to impact results. The Board believes the certain $28.00 per share all-cash consideration provided by the Alcon merger agreement exceeds what STAAR could